Parametric Portfolio Associates LLC lifted its stake in shares of Dermira Inc (NASDAQ:DERM) by 56.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,918 shares of the biopharmaceutical company’s stock after purchasing an additional 11,487 shares during the period. Parametric Portfolio Associates LLC owned about 0.08% of Dermira worth $930,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of DERM. BNP Paribas Arbitrage SA increased its stake in Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC lifted its stake in shares of Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,203 shares during the period. KCG Holdings Inc. acquired a new stake in shares of Dermira in the 1st quarter worth $215,000. Legal & General Group Plc lifted its stake in shares of Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 963 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Dermira by 12.8% in the 2nd quarter. ProShare Advisors LLC now owns 24,682 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 2,808 shares during the period. Hedge funds and other institutional investors own 99.54% of the company’s stock.
Dermira Inc (DERM) traded down $1.34 during mid-day trading on Monday, reaching $24.21. 603,657 shares of the company traded hands, compared to its average volume of 426,267. Dermira Inc has a 1-year low of $21.35 and a 1-year high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68.
Several equities research analysts recently issued reports on DERM shares. Leerink Swann reissued an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Mizuho reaffirmed a “buy” rating and set a $43.00 price target (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 target price (down from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $43.33.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Insiders sold a total of 28,200 shares of company stock valued at $794,131 over the last three months. 13.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Parametric Portfolio Associates LLC Grows Position in Dermira Inc (NASDAQ:DERM)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/parametric-portfolio-associates-llc-grows-holdings-in-dermira-inc-derm.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.